A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

NCT02497235 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

Interventions

DRUG: TAK-935
DRUG: [18F]MNI-792 (tracer)

Sponsor

Takeda